Form 4: STERIS plc Executive Reports Significant Equity Grant and Option Awards

Mary Clare Fraser, SVP & Chief HRO of STERIS plc, reported the acquisition of 2,505 ordinary shares and 8,904 employee stock options on June 3, 2025, as part of her compensation, with vesting schedules extending through 2029.

Summary

• Mary Clare Fraser, Senior Vice President & Chief Human Resources Officer of STERIS plc (STE), reported changes in her beneficial ownership of company securities.
• On June 3, 2025, Ms. Fraser acquired 2,505 ordinary shares at a transaction price of $0.00, bringing her total direct beneficial ownership of ordinary shares to 13,089.
• Of the 13,089 ordinary shares, 9,578 are restricted and will lapse in tranches: 692 on October 1, 2025; 2,313 on June 1, 2026; 2,028 on June 2, 2026; 2,040 on June 4, 2027; and 2,505 on June 5, 2028.
• Additionally, on June 3, 2025, Ms. Fraser acquired 8,904 employee stock options at a transaction price of $0.00, with an exercise price of $267.66 per share.
• These employee stock options become exercisable in four equal tranches of 2,226 options each, on June 3, 2026, June 3, 2027, June 5, 2028, and June 4, 2029, respectively.
• The employee stock options have an expiration date of June 3, 2035.
• The reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: The document reports a standard executive equity grant, which is a positive for aligning management incentives with shareholder interests. It does not contain any negative or unexpected information.

Positives

• The acquisition of ordinary shares and employee stock options by a senior executive aligns management's long-term interests with those of shareholders.
• The use of a Rule 10b5-1 plan indicates a pre-arranged trading plan, which is a positive corporate governance practice designed to prevent insider trading concerns.

Future Outlook

The future outlook for the reporting person's equity holdings includes the scheduled lapse of restrictions on 9,578 ordinary shares through June 2028 and the phased exercisability of 8,904 employee stock options through June 2029, with an ultimate expiration date in June 2035. These vesting schedules indicate a long-term incentive structure for the executive.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing details a routine equity grant to a senior executive, which is a standard component of executive compensation packages across most industries, including the healthcare and industrial services sectors where STERIS plc operates. Such grants are designed to align executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The equity grant structure, involving both restricted stock and stock options with multi-year vesting schedules, is a common practice in executive compensation across various industries, including healthcare and industrial services, aligning executive incentives with long-term company performance.
• The use of a Rule 10b5-1 plan for the transaction is also a standard corporate governance practice to mitigate insider trading concerns, consistent with best practices observed in publicly traded companies like Medtronic, Danaher, or Stryker, which also operate in related medical technology or industrial sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the interests of a key executive with long-term shareholder value, as the executive's compensation is tied to the company's stock performance.
• Employees: Standard executive compensation practices can signal stability and a commitment to retaining key talent within the company.

Next Steps

• Lapse of restrictions on ordinary shares on various dates: October 1, 2025; June 1, 2026; June 2, 2026; June 4, 2027; and June 5, 2028.
• Employee stock options becoming exercisable in tranches on June 3, 2026, June 3, 2027, June 5, 2028, and June 4, 2029.
• Expiration of employee stock options on June 3, 2035.

Key Dates

Recommendation

Keywords

STERIS plc, STE, Form 4, Insider Transaction, Equity Grant, Stock Options, Executive Compensation, Beneficial Ownership, Rule 10b5-1 Plan, Restricted Stock